- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00222820
Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study
Depression: The Search for Treatment-Relevant Phenotypes
We are doing this pilot study to learn more about four aspects of treating depression:
- The features of a depressed person's mood and anxiety and how these features affect a person's capacity to get better and stay better.
- If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication.
- Whether or not a person's personality traits affect how they respond to treatment.
- The gene involved in processing antidepressant medication
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This pilot study is an experimental investigation designed so that consenting subjects are randomly assigned to pharmacotherapeutic or psychotherapeutic interventions for depression.
For the initial phase of treatment, subjects will be randomly assigned to treatment with an SSRI, (escitalopram oxalate or citalopram hydrobromide), or with interpersonal psychotherapy (IPT). Escitalopram will be prescribed for all patients randomized to the medication arm of the study, unless the study psychiatrist determines that citalopram is more clinically appropriate. Escitalopram and citalopram are FDA-Approved SSRI antidepressants indicated for the treatment of depression. In order to optimize outcomes and emulate usual clinical practice, subjects who do not meet response criteria (defined as a 50% reduction in baseline Hamilton Rating Scale for Depression [HRS-D]) or meet stabilization criteria (defined as a mean HRS-D < 7 for 3 weeks) at acute phase Visit 7 or Visit 13 of treatment will have the other treatment added. Subjects who meet stabilization criteria (mean HRS-D < 7 for 3 weeks) at any time between acute phase Visit 13 and 21 will enter the 6-month continuation phase and continue with the treatment that led to their stabilization. Subjects who have not met stabilization criteria by acute phase Visit 21 will remain in active treatment and be offered alternative pharmacotherapy. Subjects who have not responded by acute phase Visit 32 will be discontinued from the protocol and referred for alternative treatment and care.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Western Psychaitric Institute and Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Men and women 2 Age 18-65 3. Currently experiencing an episode of major depression 4. Not currently receiving effective treatment 5. Females of childbearing potential: practicing an acceptable form of birth control 6. Subjects with suicidal ideation are eligible as long as outpatient treatment is deemed safe 7. Willingness and ability to give informed consent.
Exclusion Criteria:
- History of manic or hypomanic episodes;
- History of schizophrenia or schizoaffective disorder;
- Current primary diagnosis of anorexia nervosa or bulimia nervosa;
- Current psychosis;
- Drug and/or alcohol dependence or abuse within the past three months (episodic abuse related to mood episodes will not exclude a subject);
- Antisocial personality disorder (other Axis II disorders will not be exclusionary);
- Organic affective syndrome;
- Renal or liver disease;
- Epilepsy;
- Cardiovascular disease;
- Uncontrolled illnesses, including untreated hypertension or unstable endocrine diseases.
- Women who are or are plan to become pregnant during the course of this study
- Subjects who require inpatient treatment because of suicidal risk or psychosis
- Subjects with a well-documented history of an inability to tolerate one of the study treatments or are currently receiving treatment with an effective antidepressant therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Hamilton Rating Scale for Depression
|
Secondary Outcome Measures
Outcome Measure |
---|
Inventory of Depressive Symptoms
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ellen Frank, Ph.D., University of Pittsburgh
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Citalopram
Other Study ID Numbers
- 011015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depression
-
Stanford UniversityTerminatedMajor Depressive Disorder | Major Depressive Episode | Major Depressive Disorder, Recurrent | Major Depression Mild | Major Depression Moderate | Major Depression SevereUnited States
-
Hawler Medical UniversityCompleted
-
Centre Hospitalier Universitaire de BesanconH. Lundbeck A/SCompletedResistant Major DepressionFrance
-
First Affiliated Hospital of Zhejiang UniversityNot yet recruiting
-
University of PittsburghCompletedPostpartum Major DepressionUnited States
-
Si TianmeiUnknownMajor Depression DisorderChina
-
The Hong Kong Polytechnic UniversityNot yet recruitingHealthy | Major Depression in Remission
-
AstraZenecaCompletedNon-psychotic Unipolar Major DepressionArgentina
-
Ruijin HospitalTerminatedTreatment Resistant Major Depression DisorderChina
-
Zentrum für Integrative PsychiatrieGerman Research FoundationCompletedCognitive Performance in Major DepressionGermany
Clinical Trials on Interpersonal Psychotherapy
-
New York State Psychiatric InstituteNot yet recruitingDepression | PTSD | Anxiety | Intimate Partner Violence
-
Hopital MontfortThe Ottawa HospitalCompletedDepression | Parkinson's DiseaseCanada
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of California, San FranciscoCompletedDepression | Posttraumatic Stress DisorderChina
-
University of IowaNational Institute of Mental Health (NIMH)Completed
-
New York State Psychiatric InstituteColumbia UniversityCompletedMajor Depressive Disorder | Adjustment Disorder | Dysthymic Disorder | Depressive Disorder NOSUnited States
-
University of Colorado, DenverAmerican Psychological Association (APA)CompletedPolycystic Ovary Syndrome | Interpersonal PsychotherapyUnited States
-
University of IowaNational Institute of Mental Health (NIMH)Terminated
-
Eunice Kennedy Shriver National Institute of Child...CompletedOverweight | Overweight AdolescentsUnited States
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Completed